Anybody looking at AZN for the first time as potential IRA investment only need look at the 5 yeat chart and ask themselves whether it has the shape they would want in a retirement account.
M
Excellent earnings . Market conditions in correct or we see new 52 week highs
A
I bought this in 2019 at 6300 and just left it for the children as savings. It’s grown steady and I’m hoping the children don’t want the money any time soon as I see this growing a lot more
C
I figure next ex div date is a ways off so I sold in the $70's over the last few weeks just hoping for the opportunity to get back in which today provided.
s
buy now.... get on the bus before it leaves without you.
The U.S, government this summer plans decisive Phase III trials of coronavirus vaccine candidates from three drugmakers, a media report said.
The Wall Street Journal reported that candidate vaccines from Moderna (MRNA) -, AstraZeneca (AZN) - with Oxford University, and Johnson & Johnson (JNJ ) - will be studied.
The government plans to fund and conduct definitive studies of the vaccines, John Mascola, director of the vaccine research center at the National Institute of Allergy and Infectious Diseases, told the Journal.
Moderna’s vaccine is scheduled first, in July. Then comes the AstraZeneca/Oxford vaccine in August and J&J’s vaccine in September, he said.
That timing indicates success for researchers who are pushing their vaccines through early test phases, the Journal notes.
Meanwhile, Eli Lilly LLY may see its coronavirus treatment medicine authorized for use as soon as September if it succeeds with tests of either of its two antibody therapies, Chief Scientific Officer Daniel Skovronsky told Reuters.
When it comes to AstraZeneca’s stock, “we don’t expect the vaccine development to impact AstraZeneca’s valuation, as the firm expects to deliver the vaccine on a non-profit basis,” Morningstar analyst Damien Conover wrote in a report last month.
“Also, government contributions will fund a heavy amount of the development and manufacturing expenses, relieving Astra of significant costs.” He maintains a wide-moat rating for the company.
One positive: “The potential vaccine could build an enormous amount of goodwill that could improve other drug-pricing negotiations, especially with governments of the world. This non-profit vaccine strategy follows a similar pathway as Johnson & Johnson,” Conover said.
AstraZeneca American depositary receipts on Wednesday closed at $53.64, up 1.7%. Johnson & Johnson shares closed at $147.72, up 1.2%. And Moderna shares closed at $60.07, up 3.2%.
Over the past three months J&J stock has risen 8%, AstraZeneca has gained 19% and Moderna has more than doubled.
Lilly stock closed at $151 on Wednesday, up 1.3%.
N
1 billion funding = test results are known to pass and will be made public shortly:
A Phase I/II clinical trial of AZD1222 began last month to assess safety, immunogenicity and efficacy in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. Data from the trial is expected shortly which, if positive, would lead to late-stage trials in a number of countries. AstraZeneca recognises that the vaccine may not work but is committed to progressing the clinical program with speed and scaling up manufacturing at risk. The Company’s comprehensive pandemic response also includes rapid mobilisation of AstraZeneca’s global research efforts to discover novel coronavirus-neutralising antibodies to prevent and treat progression of the COVID-19 disease, with the aim of reaching clinical trials in the next three to five months. Additionally, the Company has quickly moved into testing of new and existing medicines across multiple therapy areas to treat the infection.
S
Best investment for rest of year - all of 2021 - AZN It sounds like scientists in Britain will have a Christmas present for some of us — a working coronavirus vaccine. Let’s connect the dots.
Researchers at Oxford and AstraZeneca have been working on a COVID-19 vaccine for months, and now the professor leading the project says the vaccine may be ready by Christmas time.
AZN - a "Strong Buy" of a Lifetime
s
ASTRA ZENECA Astra Zeneca rises on positive analysis from investment banks (Finwire) 2020-11-30 13:03 Pharmaceutical giant Astra Zeneca rises almost 1.4 percent on the stock exchange after positive analyzes from Cowen and UBS with higher target prices.
According to Bloomberg News, the analyst in charge at investment bank Cowen believes that Astra Zeneca is a top pick in the pharmaceutical sector with good growth prospects.
Cowen is of the opinion that Astra Zeneca offers first-class growth, which justifies the high valuation. It points to a momentum for pharmaceutical products as well as productivity when it comes to research and development.
Furthermore, Astra Zeneca has relatively low exposure to the US, which makes the company less vulnerable to potential reforms there. This at the same time as the pharmaceutical giant has significant exposure to emerging markets.
At the same time, UBS chooses to raise its recommendation to neutral from sales, after the price has dropped significantly in the wake of the interim results from the corona vaccine. The target price is raised to 95 British pounds (73).
Carl Becht carl.becht@finwire.se News agency Finwire
S
we've now moved on from trial data to real data. In the UK, both the Pfizer and AZN vaccines have proven to be safe and effective. After 11.5 million vaccinated, it's clear that both vaccines are performing as expected. Even better: data is available in such quantity to see that the vaccine not only prevents serious symptoms, it also reduces spreading. This is excellent news. But as has been noted many times, AZN won't make a profit from this until June/July - then it will make a fortune. it's likely that this vaccine will be the dominant player in future years due to its ease of manufacture, storage and distribution. Meanwhile, AZN has a huge portfolio of innovative drugs on the market. The future's bright!
AstraZeneca COVID drug neutralises Omicron sub-variants in lab study | Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-antibody-cocktail-retains-activity-against-omicron-subvariants-2022-03-21/
comments?
The Wall Street Journal reported that candidate vaccines from Moderna (MRNA) -, AstraZeneca (AZN) - with Oxford University, and Johnson & Johnson (JNJ ) - will be studied.
The government plans to fund and conduct definitive studies of the vaccines, John Mascola, director of the vaccine research center at the National Institute of Allergy and Infectious Diseases, told the Journal.
Moderna’s vaccine is scheduled first, in July. Then comes the AstraZeneca/Oxford vaccine in August and J&J’s vaccine in September, he said.
That timing indicates success for researchers who are pushing their vaccines through early test phases, the Journal notes.
Meanwhile, Eli Lilly LLY may see its coronavirus treatment medicine authorized for use as soon as September if it succeeds with tests of either of its two antibody therapies, Chief Scientific Officer Daniel Skovronsky told Reuters.
When it comes to AstraZeneca’s stock, “we don’t expect the vaccine development to impact AstraZeneca’s valuation, as the firm expects to deliver the vaccine on a non-profit basis,” Morningstar analyst Damien Conover wrote in a report last month.
“Also, government contributions will fund a heavy amount of the development and manufacturing expenses, relieving Astra of significant costs.” He maintains a wide-moat rating for the company.
One positive: “The potential vaccine could build an enormous amount of goodwill that could improve other drug-pricing negotiations, especially with governments of the world. This non-profit vaccine strategy follows a similar pathway as Johnson & Johnson,” Conover said.
AstraZeneca American depositary receipts on Wednesday closed at $53.64, up 1.7%. Johnson & Johnson shares closed at $147.72, up 1.2%. And Moderna shares closed at $60.07, up 3.2%.
Over the past three months J&J stock has risen 8%, AstraZeneca has gained 19% and Moderna has more than doubled.
Lilly stock closed at $151 on Wednesday, up 1.3%.
A Phase I/II clinical trial of AZD1222 began last month to assess safety, immunogenicity and efficacy in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. Data from the trial is expected shortly which, if positive, would lead to late-stage trials in a number of countries. AstraZeneca recognises that the vaccine may not work but is committed to progressing the clinical program with speed and scaling up manufacturing at risk.
The Company’s comprehensive pandemic response also includes rapid mobilisation of AstraZeneca’s global research efforts to discover novel coronavirus-neutralising antibodies to prevent and treat progression of the COVID-19 disease, with the aim of reaching clinical trials in the next three to five months. Additionally, the Company has quickly moved into testing of new and existing medicines across multiple therapy areas to treat the infection.
It sounds like scientists in Britain will have a Christmas present for some of us — a working coronavirus vaccine. Let’s connect the dots.
Researchers at Oxford and AstraZeneca have been working on a COVID-19 vaccine for months, and now the professor leading the project says the vaccine may be ready by Christmas time.
AZN - a "Strong Buy" of a Lifetime
Astra Zeneca rises on positive analysis from investment banks (Finwire)
2020-11-30 13:03
Pharmaceutical giant Astra Zeneca rises almost 1.4 percent on the stock exchange after positive analyzes from Cowen and UBS with higher target prices.
According to Bloomberg News, the analyst in charge at investment bank Cowen believes that Astra Zeneca is a top pick in the pharmaceutical sector with good growth prospects.
Cowen is of the opinion that Astra Zeneca offers first-class growth, which justifies the high valuation. It points to a momentum for pharmaceutical products as well as productivity when it comes to research and development.
Furthermore, Astra Zeneca has relatively low exposure to the US, which makes the company less vulnerable to potential reforms there. This at the same time as the pharmaceutical giant has significant exposure to emerging markets.
At the same time, UBS chooses to raise its recommendation to neutral from sales, after the price has dropped significantly in the wake of the interim results from the corona vaccine. The target price is raised to 95 British pounds (73).
Carl Becht
carl.becht@finwire.se
News agency Finwire